Related Experiment Video
Updated: May 24, 2025

Author Spotlight: Treating Frozen Shoulder with Small Needle Knife Therapy
Published on: November 17, 2023
Evaluation of internally cooled radiofrequency ablation targeting multiple shoulder nerves for chronic shoulder pain
Mitsukuni Yoshida1, Peter K Park1,2, Loc V Thang1
1Division of Pain Medicine, Department of Anesthesiology, Washington University School of Medicine, St Louis, MO, United States.
Objective:
Shoulder pain is a prevalent musculoskeletal disorder, affecting up to 70% of adults over their lifetimes. Recently, radiofrequency ablation (RFA) has gained attention as a treatment for joint pain. This study aims to evaluate the efficacy of internally cooled RFA (icRFA) in alleviating shoulder pain and improving both qualitative and quantitative measures of shoulder function.
Design:
Prospective cohort study.
Subjects:
Patients with chronic shoulder pain (n = 35) who responded positively to diagnostic blocks of the suprascapular nerve (SSN), axillary nerve (AN), and lateral pectoral nerve (LPN).
Methods:
Patients underwent icRFA targeting the SSN, AN, and LPN. Treatment response was assessed with the numeric rating scale (NRS) for pain, the American Shoulder and Elbow Surgeons (ASES) score, and active range of motion (AROM) in flexion and abduction. Outcomes were measured at baseline and at 1, 3, and 6 months after icRFA. Patient characteristics were compared between responders and nonresponders to icRFA treatment, and correlation analyses were conducted to explore the relationship between pain relief and functional improvement.
Results:
NRS pain levels significantly decreased at 1 month (Adjusted [Adj.] P < .0001), 3 months (Adj. P < .0001), and 6 months (Adj. P = .0002) after icRFA. ASES score improved at 1 month (Adj. P < .0001), 3 months (Adj. P < .0001), and 6 months (Adj. P < .0001) after icRFA. Flexion AROM improved at 1 month (Adj. P < .0001), 3 months (Adj. P < .0001), and 6 months (Adj. P = .0139) after icRFA. Abduction AROM improved at 1 month (Adj. P < .0001), 3 months (Adj. P < .0001), and 6 months (Adj. P < .0001) after icRFA.
Conclusion:
iccRFA targeting the SSN, AN, and LPN is a safe and effective intervention, providing significant improvements in pain, functional activities of daily living, and AROM of the shoulder for at least 6 months.
More Related Videos
08:20Author Spotlight: Unveiling the Therapeutic Effects of FSN Treatment – Bridging Research and Clinical Applications in Neuropathic Pain
Published on: June 30, 2023
05:43Author Spotlight: Improving Lesion Contiguity in Pulmonary Vein Isolation via Proactive Esophageal Cooling
Published on: April 19, 2024